Guidance for Vertex Pharmaceuticals Incorporated (VRTX)
| Period | Range | Estimate | Revenue Range | Revenue Estimate | Target | Details |
|---|---|---|---|---|---|---|
| 2026 | N/A | N/A | $12.95B – 13.10B | $13.00B | = Maintained | Details |
| 2025 | N/A | N/A | $11.90B – 12.00B | $12.00B | = Maintained | Details |
| 2025 | N/A | N/A | $11.85B – 12.00B | $11.94B | = Maintained | Details |
| 2025 | N/A | N/A | $11.85B – 12.00B | $11.98B | = Maintained | Details |
| 2025 | N/A | N/A | $11.75B – 12.00B | $11.85B | = Maintained | Details |
| 2024 | N/A | N/A | $10.80B – 10.90B | $10.76B | = Maintained | Details |
| 2024 | N/A | N/A | $10.65B – 10.85B | $10.76B | = Maintained | Details |
| 2024 | N/A | N/A | $10.55B – 10.75B | $10.72B | = Maintained | Details |
| Q1 2024 | N/A | N/A | $10.55B – 10.75B | $10.61B | = Maintained | Details |
| 2023 | N/A | N/A | $9.85B | $9.87B | = Maintained | Details |
| 2023 | N/A | N/A | $9.55B – 9.70B | $9.70B | = Maintained | Details |
| Q1 2023 | N/A | N/A | $9.55B – 9.70B | $9.60B | = Maintained | Details |
| 2022 | N/A | N/A | $8.80B – 8.90B | $8.77B | Raised |
Details |
| 2022 | N/A | N/A | $8.60B – 8.80B | $8.58B | Raised |
Details |
| 2022 | N/A | N/A | $8.40B – 8.60B | $8.58B | = Maintained | Details |
| 2022 | N/A | N/A | $8.40B – 8.60B | $8.22B | Raised |
Details |
| 2021 | N/A | N/A | $7.40B – 7.50B | $7.32B | Raised |
Details |
| 2021 | N/A | N/A | $7.20B – 7.40B | $6.99B | = Maintained | Details |
| 2021 | N/A | N/A | $6.70B – 6.90B | $6.95B | = Maintained | Details |
| 2020 | N/A | N/A | $5.70B – 5.90B | $5.73B | = Maintained | Details |
| 2020 | N/A | N/A | $5.30B – 5.60B | $5.33B | = Maintained | Details |
| 2020 | N/A | N/A | $5.10B – 5.30B | $4.87B | = Maintained | Details |
| 2019 | N/A | N/A | $3.70B – 3.75B | $3.74B | = Maintained | Details |
| 2019 | N/A | N/A | $3.60B – 3.70B | $3.55B | = Maintained | Details |
| 2019 | N/A | N/A | $3.45B – 3.55B | $3.56B | = Maintained | Details |
| 2019 | N/A | N/A | $3.45B – 3.55B | $3.55B | = Maintained | Details |
| Q3 2018 | N/A | N/A | N/A | N/A | = Maintained | Details |
| Q2 2018 | N/A | N/A | N/A | N/A | = Maintained | Details |
| Q1 2018 | N/A | N/A | N/A | N/A | = Maintained | Details |
| 2017 | N/A | N/A | $2.10B – 2.50B | $2.30B | = Maintained | Details |
| Q3 2017 | N/A | N/A | N/A | N/A | = Maintained | Details |
| Q2 2017 | N/A | N/A | N/A | N/A | = Maintained | Details |
| Q1 2017 | N/A | N/A | N/A | N/A | = Maintained | Details |
| 2014 | N/A | N/A | $570.00M – 600.00M | $620.70M | = Maintained | Details |
| 2013 | N/A | N/A | $1.00M – 1.05M | $1.17M | Lowered |
Details |
| 2013 | N/A | N/A | $1.10B – 1.20B | $1.20B | Lowered |
Details |
| 2013 | N/A | N/A | $1.10B – 1.25B | $1.16B | = Maintained | Details |


Raised
Lowered